DOD Vision, Clinical Trial Award

0
2

Funding Opportunity ID:333523
Opportunity Number:W81XWH-21-VRP-CTA
Opportunity Title:DOD Vision, Clinical Trial Award
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Cooperative Agreement
Grant
Category of Funding Activity:Science and Technology and other Research and Development
Category Explanation:
CFDA Number(s):12.420
Eligible Applicants:Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:
Agency Code:DOD-AMRAA
Agency Name:Department of Defense
Dept. of the Army — USAMRAA
Posted Date:May 14, 2021
Close Date:Nov 16, 2021
Last Updated Date:May 14, 2021
Award Ceiling:$0
Award Floor:$0
Estimated Total Program Funding:$20,000,000
Expected Number of Awards:1
Description:The FY21 VRP CTA supports the rapid implementation of early-phase clinical trials (i.e., phase 0 through phase 2a) of new interventions with the potential to have a significant impact on service-connected eye injury and visual dysfunction. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies.Funding from this award mechanism must support a clinical trial. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Funded trials are required to post a copy of the Institutional Review Board (IRB)-approved informed consent form used to enroll subjects on a publicly available federal website in accordance with federal requirements described in the Code of Federal Regulations, Title 32, Part 219 (32 CFR 219).
Version:1





Visit the Official Webpage For More Details on DOD Vision, Clinical Trial Award

LEAVE A REPLY

Please enter your comment!
Please enter your name here